Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Globe Newswire•03/11/2026•08:00 ET
0
Key Highlights
- ➤VOQUEZNA eligible commercially insured patients may pay as little as $0 through BlinkRx
- ➤BlinkRx provides free home delivery, automatic lowest-cost identification, and prior authorization support
- ➤Eligible Massachusetts patients may pay as little as $25 for a 30-day supply
- ➤Eligible uninsured patients may pay as little as $55 for a 30-day supply through BlinkRx
Expert Statements
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“We believe that patients with GERD who are prescribed VOQUEZNA should be able to start and stay on their medication, without unnecessary cost or paperwork getting in the way”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“By partnering with BlinkRx, we’re working to make VOQUEZNA easier and more affordable to access, with eligible commercially insured patients now having the potential to pay as little as $0, as well as continuing to offer a cash-pay option for those without insurance coverage.”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“For many people living with GERD, finding the right treatment can be a long journey. Once their doctor prescribes VOQUEZNA, starting treatment should be the easy part.”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“This initiative reflects our focus on putting patients first.”
* Potential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed
A Media Snippet accompanying this announcement is available by clicking on this link.
Get started
Create a free account to read the full story.